The privately held San Carlos companyreported data Tuesday from a Phase IIa trial of its drug, called ALV-003, that it believes makes it the first mid-stage celiac disease study to meet predetermined goals. It plans to start a Phase IIb trial later this year.
No comments:
Post a Comment